Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P36
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -1.35% |
| Q3 2025 | 12.71% |
| Q2 2025 | -3.55% |
| Q1 2025 | -17.55% |
| Q4 2024 | 12.82% |
| Q3 2024 | 37.10% |
| Q2 2024 | -6.56% |
| Q1 2024 | 3.70% |
| Q4 2023 | 36.59% |
| Q3 2023 | 41.84% |
| Q2 2023 | 26.20% |
| Q1 2023 | -3.33% |
| Q4 2022 | 18.99% |
| Q3 2022 | -22.09% |
| Q2 2022 | -9.45% |
| Q1 2022 | 1.17% |
| Q4 2021 | 12.99% |
| Q3 2021 | 9.38% |
| Q2 2021 | 14.54% |
| Q1 2021 | -24.76% |
| Q4 2020 | 26.54% |
| Q3 2020 | -26.19% |
| Q2 2020 | 15.84% |
| Q1 2020 | -17.10% |
| Q4 2019 | -1.53% |
| Q3 2019 | 20.48% |
| Q2 2019 | 2.90% |
| Q1 2019 | 21.96% |
| Q4 2018 | 32.13% |
| Q3 2018 | -2.12% |
| Q2 2018 | 32.78% |
| Q1 2018 | 18.63% |
| Q4 2017 | -7.18% |
| Q3 2017 | 6.92% |
| Q2 2017 | 17.90% |
| Q1 2017 | 4.39% |
| Q4 2016 | -11.96% |
| Q3 2016 | 21.83% |
| Q2 2016 | 22.91% |
| Q1 2016 | -9.33% |